Malignant melanoma staging using whole-body positron emission tomography

Melanoma Research

Volumn 8, Issue 1, 1998, Pages 59-62

  Paquet, P ^a   Hustinx, R ^a   Rigo, P ^a   Pierard G E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Metastasis; Positron emission tomography; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; WHOLE BODY RADIATION;

AGED; ANIMALS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0031916526     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199802000-00010     Document Type: Article

References (15)

1. McCarthy WH, Shaw HM. The influence of prognosticfactors on melanoma management. In: Lejeune FJ, Chaudhuri PK, Das Gupta T, eds. Malignant Melanoma: medical and surgical management. New York: McGraw-Hill, 1994: 171-185.
2. Gritters LS, Francis IR, Zasadny KR, et al. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993; 34: 1420-1427.
3. Wahl RL, Hutchins GD, Buchsbaum DJ. Fluorine-18-2-deoxy-2-fluoro-D-glucose (FDG) uptake into human tumor xenografts: feasibility studies for cancer imaging with PET. Cancer 1991; 67: 1544-1549.
4. Buzaid AC, Sandier AB, Maani S. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993; 11: 638-643.
5. Blessing C, Feine U, Geiger L, et al. Positron emission tomography and ultrasonography. Arch Dermatol 1995; 131: 1394-1398.
6. Boni R, Boni RAH, Steinert H, et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995; 132: 556-562.
7. Steinert HC, Boni RAH, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 1995; 195: 1705-1709.
8. Pounds TR, Valk PE, Haseman MK, et al. Whole-body PET-FDG imaging in diagnosis of metastatic melanoma: comparison to CT. J Nucl Med 1995; 36: 116P.
9. Argenyi EE, Urdanela LF, Whitaker DC, et al. Clinical utility of F-18 FDG and PET imaging in detecting metastatic melanoma. J Nucl Med 1995; 36: 193P.
10. Wöhrle H, Feine U, Geiger L, et al. Whole body 18-FDG PET in 46 patients with recurrent malignant melanomas: a comparison versus CT and MRI. Eur J Nucl Med 1995; 22: 753.
11. Wagner JD, Schauwecker D, Hutchins G, Caleman JJ. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 1997; 64: 181-189.
12. Fierlbeck G, Blessing C, Feine V, Laniads M. Positron emission tomography. A new diagnostic approach in metastatic melanoma. Aust J Dermatol 1997; 38: (suppl 2): 155.
13. 18F)-fluorodeoxy-glucose uptake in abdominal abscesses: a PET study. J Comput Assist Tomogr 1989; 13: 829-831.
14. 18F-2-fluoro-2-deoxy-D-glucose (FDG) in infection and in reactive lymph nodes. J Nucl Med 1992; 33: 925.
15. Wahl RL, Kaminski MS, Elhier SP, Hutchins GD. The potential of 2-deoxy-2(F18)-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. J Nucl Med 1990; 31: 1831-1834.